- Home
- HOWL vs THTX Comparison
HOWL vs THTX Comparison
Compare HOWL & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- THTX
- Stock Information
- Founded
- HOWL 2017
- THTX 1993
- Country
- HOWL United States
- THTX Canada
- Employees
- HOWL N/A
- THTX N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- THTX Health Care
- Exchange
- HOWL Nasdaq
- THTX Nasdaq
- Market Cap
- HOWL 87.4M
- THTX 93.3M
- IPO Year
- HOWL 2021
- THTX N/A
- Fundamental
- Price
- HOWL $1.41
- THTX $1.53
- Analyst Decision
- HOWL Strong Buy
- THTX Hold
- Analyst Count
- HOWL 2
- THTX 1
- Target Price
- HOWL $9.50
- THTX N/A
- AVG Volume (30 Days)
- HOWL 280.2K
- THTX 108.7K
- Earning Date
- HOWL 03-06-2025
- THTX 02-19-2025
- Dividend Yield
- HOWL N/A
- THTX N/A
- EPS Growth
- HOWL N/A
- THTX N/A
- EPS
- HOWL N/A
- THTX N/A
- Revenue
- HOWL $3,386,000.00
- THTX $84,316,000.00
- Revenue This Year
- HOWL N/A
- THTX $5.78
- Revenue Next Year
- HOWL $34.17
- THTX $2.47
- P/E Ratio
- HOWL N/A
- THTX N/A
- Revenue Growth
- HOWL N/A
- THTX 5.75
- 52 Week Low
- HOWL $1.26
- THTX $1.08
- 52 Week High
- HOWL $8.19
- THTX $2.18
- Technical
- Relative Strength Index (RSI)
- HOWL 41.51
- THTX 38.50
- Support Level
- HOWL $1.28
- THTX $1.37
- Resistance Level
- HOWL $1.42
- THTX $1.50
- Average True Range (ATR)
- HOWL 0.09
- THTX 0.09
- MACD
- HOWL 0.01
- THTX -0.04
- Stochastic Oscillator
- HOWL 49.93
- THTX 23.26
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.